Viewing Study NCT05100134

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:18 AM
Ignite Modification Date: 2026-04-21 @ 1:40 PM
Study NCT ID: NCT05100134
Status: AVAILABLE
Last Update Posted: 2025-12-09
First Post: 2021-10-19
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Managed Access Programs for LDK378, Ceritinib
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anaplastic Lymphoma Kinase (ALK)- Positive Tumors View
None Non-small Cell Lung Cancer (NSCLC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None MAP View
None Manage access program View
None ceritinib View
None ALK positive tumors View
None Non-small cell lung cancer (NSCLC) View
None Anaplastic large cell lymphoma (ALCL) View
None Inflammatory myofibroblastic tumour (IMT), View
None LDK378 View